HKSE - Delayed Quote HKD

JACOBIO-B (1167.HK)

1.420

-0.050

(-3.40%)

At close: January 28 at 12:08:04 PM GMT+8

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting.

PR Newswire 24 days ago

JBPHF
Meriaura Group Oyj And 2 Other Promising Penny Stocks

As global markets navigate a complex landscape marked by fluctuating consumer confidence and mixed economic indicators, investors are exploring diverse opportunities for growth. Penny stocks, although an older term, remain significant as they often represent smaller or newer companies with the potential for substantial returns when supported by strong financials. In this article, we will examine three penny stocks that demonstrate balance sheet strength and long-term potential, offering...

Simply Wall St. 29 days ago

2HRA.DE

JBPHF

MERIS.ST
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California.

PR Newswire last month

JBPHF
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals Co., Ltd (688578.SH).

PR Newswire 4 months ago

JBPHF
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung cancer (NSCLC) patients harboring KRAS G12C mutation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting as form of oral presentation. Jacobio also presented updated data of pivotal phase II study of glecirasib as form of oral presenta

PR Newswire 7 months ago

JBPHF
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint

Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online.

PR Newswire 8 months ago

JBPHF
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2024 (the "AACR 2024") from April 5 to 10, 2024.

PR Newswire 9 months ago

JBPHF
Jacobio Pharma Announces 2023 Annual Results

Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was RMB 1.2 billion. Jacobio Pharma also announced its recent business progress and expected milestones.

PR Newswire 9 months ago

JBPHF
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.

Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of the U.S. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300. Jacobio also plans to submit IND in China, and will conduct clinical studies once receives the IND approval.

PR Newswire 10 months ago

JBPHF
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhibitor glecirasib and novel SHP2 inhibitor JAB-3312. JAB-3312 is the first SHP2 inhibitor entered into phase III study globally in combination with KRAS G12C inhibitor.

PR Newswire 11 months ago

JBPHF

Performance Overview

Return	1167.HK	HANG SENG INDEX
YTD	+9.23%	+0.92%
1-Year	-48.18%	+26.79%
3-Year	-85.10%	-15.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

JACOBIO-B (1167.HK)

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

Meriaura Group Oyj And 2 Other Promising Penny Stocks

Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH

Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China

Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Jacobio Pharma Announces 2023 Annual Results

Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

Performance Overview